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Abstract Multiple sclerosis (MS) is a chronic autoimmune
disease, where T-cells attack the myelin sheath in the central
nervous system (CNS), characterized by relapsing-remitting
episodes, or gradually increasing severity of symptoms and
disability that accumulate over time. While current MS
therapies have been proven in clinical trials to provide
significant benefits, they cater only to subsets of patients.
Moreover, there is an acute need to identify the most effective
and safe treatment appropriate for each patient prospectively,
since early intervention has been proven to prevent accumula-
tion of irreversible dysfunction. In this review we discuss the
current state-of-the-art in pharmacogenetic research as applied
to the common marketed and in-development MS treatments,
with respect to both efficacy and safety aspects. We conclude
by discussing the relevance of pharmacogenetics and other
biomarkers to the prediction, prevention and personalization of
MS medications in the horizon.
Keywords Multiple Sclerosis . Pharmacogenetics .
Personalized medicine . Polymorphism . Predictive
diagnostics . Preventive measures
Multiple sclerosis: clinical characteristics
and pathoetiology
Multiple Sclerosis (MS) is the most common chronic
neurological disease affecting young adults, with onset
usually at the second to fourth decade of life [1].
Similarly to other autoimmune diseases, women are
affected 3–4 times more often than men [1]. The
pathoetiology of the disease is complex, with multiple
factors influencing the mode of the disease, its severity
and the progression rate. Epidemiological studies have
clearly indicated that both genetic and environmental
factors determine and modify the disease [1]. The two
main clinical subtypes that characterize the onset of the
disease are the relapsing-remitting (RRMS) and primary
progressive (PPMS) disease courses, accounting for 85%
and 10–15% of all MS cases, respectively [2]. It should be
noted, that over two thirds of RR patients will succumb to
a secondary progressive (SPMS) disease mode within 10–
15 years. Other rarer disease subtypes include the
extremely active form (malignant MS) and the mild type
(benign MS). MS is characterized clinically by the
manifestation of acute, as well as chronically accumulat-
ing symptoms, including numbness, motor weakness,
optic neuritis, incoordination, diplopia, dizziness and
vertigo. Other accompanying symptoms and signs may
include fatigue, urinary urgency or retention, depression,
heat intolerance, pain, cognitive dysfunction, spasticity,
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The underlying pathology that leads to clinical disability
is comprised of intricate relationships between three
disrupted processes involving the myelin sheath (mainly
oligodendocytes) that wraps central nervous system (CNS)
neurons: (a) the inflammatory axis involves the invasion of
immune cells with aberrant activity into the CNS, where
they attack the myelin components, a process termed
demyelination and resulting in secondary neurodegenera-
tion. This process subsequently leads to axonal and
neuronal loss; (b) the primary neurodegeneration axis
involves primary axonal and neuronal loss without triggers
or signs of prominent inflammation; and (c) the impaired
repair axis involves unsuccessful repair attempts by the
CNS to mend the damage accumulated through insults from
the other two processes. Unfortunately, this is but a partial
and incomplete repair process, which is often the basis of
residual deficits and disability. The dynamic interactions
between these three processes are characterized by periods
of acute attacks, interspaced by remissions during which
chronic disability is accumulated. The attacks are mani-
fested through paralysis, visual loss and other symptoms
prohibiting the normal conduct of activities of daily living.
These offensives occur due to an over-activation of immune
cells in the inflammatory axis. The chronic phase of the
disease, on the other hand, is considered to be dominated by
the neurodegenerative processes. In this fashion, repair is
mainly noted once the acute attack fades off and may give rise
to spontaneous recovery that in the early phase of the disease
does not necessitate pharmaceutical intervention. Triggers for
initiation, duration, severity and rate of attacks can be both
environmental and inherited and it is as yet unclear how to
predict the disease course in any given patient.
The differential diagnoses of MS include, at early stages,
cerebrovascular disease, epilepsy, vitamin-B12 deficiency
and neuropathy. As disease progresses and neuroimaging
techniques are employed (e.g. MRI), conditions that may
appear similar to MS include vasculitis, congenital bio-
chemical disorders, viral infection and lupus (SLE). Lastly,
neuromyelitis optica (NMO) is a severe inflammation and
astrocyte loss with profound demyelination in the optic
nerves and the spinal cord. NMO symptoms are similar to
MS (e.g., vision loss, muscle weakness, numbness and
paralysis in the arms and legs, etc), and therefore in the
past, NMO was considered a severe form of MS. However,
research has shown that this condition results from the
production of pathogenic autoantibodies against the water
channel aquaporin-4 (AQP-4) on astrocytes [3]. This is
therefore one important example where biomarkers serve as
essential diagnosis tools. By screening NMO immunoglo-
bulins (NMO-IgG) in serum it is now possible to accurately
diagnose this condition and provide the required course of
treatment. While acute attacks are treated similarly in MS
and NMO (intravenous steroids), chronic treatment by IFN-
β and GA does not seem to be beneficial in the case of
NMO, but rather oral steroid medication and immunosup-
pressive drugs (e.g. azathioprine) may be used [4, 5]. In this
case, early diagnosis is critical, since NMO immunosup-
pressive therapy is necessary to prevent attack-related
disability. Indeed, this is one gateway to personalization
facilitated by biomarkers in this therapeutic area.
Multiple sclerosis: nature versus nurture
Despite decades of research it is still debatable to what
extent genetic factors, environmental variables, and inter-
actions between them cause and modify MS disease
susceptibility. A common method used to estimate the
contribution of genetics employs heritability testing (h2) in
kinships, and particularly in monozygotic (MZ) versus
dizygotic (DZ) twins. A recent meta-analysis [6] suggests
that commonly used methodology for estimating heritabil-
ity has been largely non-informative and yielded mean
estimates that are weak in North America and France (h2:
0.25–0.31); moderate in Italy (h2: 0.45); and high in the
UK, Canada and Denmark (h2: 0.53–0.76). Moreover,
confidence intervals literally span the entire gamut, ranging
from zero to 0.94 [6]. The limited utility of these estimates
stems both from flaws in heritability analysis [7], as well as
the low disease prevalence and the challenges of collecting
unbiased informative twin pairs. It is therefore important to
employ other types of family-based data, such as cohorts of
adoptee, half-sibling step-siblings and conjugal pedigrees in
order to address questions about the extent to which MS
susceptibility is heritable [7]. Overall, reported studies
suggest that MS indeed has a substantial genetic basis
(possibly with maternal parent-of-origin effect), although
the number and size of studies published thus far are small.
Clearly, environmental factors play a significant role in
the determination and modification of MS disease risk,
progression and severity in addition and in combination
with the effects of genetic factors. The unique geography of
the disease, for instance, indicates a latitude effect that
seems to alter risk estimates upon immigration [2]. It should
be pointed, though, that the geographical features of the
disease are complex and thus the irregular disease distribu-
tion pattern in secluded populations, such as Sardinia and
the Inuit population in Canada, may support the hypothesis
of a genetic etiology as well. Other lines of evidence
support the contribution of environmental factors to MS
etiology, including sunlight and ultraviolet radiation and
vitamin D intake. Intensive investigation has been devoted
to the influence of viral infections, primarily Epstein-Barr
and Herpes simplex. These were recently reviewed by Milo
and Kahan [2]. Another possible type of modifying factors
relates to epigenetics, the study of changes in gene function
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that are mitotically and/or meiotically heritable and that do
not entail a change in DNA sequence [8]. The parent-of-
origin and gender-specific effects noted in MS disease risk
support the possibility of an epigenetic involvement, with
the human leukocyte antigen (HLA) region effects pub-
lished recently [9].
The main genetic association with MS disease suscep-
tibility in northern Europeans has been shown with
extended major histocompatibility complex (MHC) haplo-
types, especially those containing HLADRB1*1501 (HLA
DRb1 gene, 1501 allele), odds ratio (OR)=7.5 for a
dominant allele-dose effect [10]. The HLADBR5*0101
allele, which is strongly correlated with HLADRB1*1501,
has been found to act as a modifying factor in interaction
(epistasis) with the latter, affecting disease severity rather
than susceptibility [11]. Other secondary signals to the
DRB1*1501 allele in the HLA region have been found,
with the top associated single nucleotide polymorphisms
(SNPs) correlating with the HLA-B*4402 [12],
HLADRB1*08 [10], HLA-DRB1*01 and HLA-DRB1*10
[13] alleles. A protective effect has been registered for the
HLA-DRB1*14 allele [10]. Other complex epistatic inter-
actions have been registered, where HLA-DQA1*0102
strongly interacts with HLADRB1*1501, so that in the
presence of the latter MS risk is increased, while in its
absence a protective effect has been registered [13]. In this
context it should be noted that a recent publication suggests
that the HLA*DRB profile of NMO patients is different
from that observed for MS patients: DRB3 is over-
represented in NMO patients, while DRB1 and DRB5 are
over-abundant in MS patients [14]. This differential genetic
signature serves both to support the progressively accepted
claim that the two conditions are underlined by different
etiologies, as well as assists in delineating the associated
pathways and assessing novel therapies for each condition.
In addition to the HLA region, modest associations with
MS susceptibility have been published and replicated for
IL7R [15, 16], IL2R [17], EVI5 [18], CLEC16A and KIF1B
[19]. The largest OR reported for a non-HLA variant was
1.34 in sporadic MS and 1.74 in multiplex families [20].
Indeed, functional studies have long shown a biological
interaction between the HLA and KIR (killer immunoglob-
ulin receptor) gene products (such as KIF1B) that seems to
explain the reported genetic signatures [21]. Overall, most
of the association data available to-date originated from
candidate gene studies supplemented by functional analy-
ses. These studies included admixture mapping strategies
that were able to narrow down the association interval by
studying populations with different linkage disequilibrium
(LD) block structure (i.e. genomic sequences with dissim-
ilar patterns of co-inheritance across populations with
divergent geneology, such as European Caucasians versus
African Americans) [22]. Recent years have seen the
reports of genome wide association studies (GWAS), which
screen the entire genome for SNPs using off-the-shelf
chips. This methodology has been useful in highlighting
common variations in regions of interest along the genome.
A meta-analysis of a total of 2,624 MS cases and 7,220
controls, which was then replicated in additional 2,215
cases and 2,116 controls, pinpointed TNFRSF1A, IRF8, and
CD6 with high significance level (combined p value <6×10
(−6)) and ORs <1.6. It should be noted that in the same
cohort the HLA-DRB1*1501 tagging SNP rs3135388 was
associated with MS susceptibility at an OR of 2.75 and a
combined p value of 3.8×10(−225) for a minor allele
frequency (MAF) of 20%. The highest OR registered for a
novel non-HLA association was found for a rare allele with
an MAF of only 2%.
Genetic studies serve not only to highlight disease specific
risk polymorphisms, but may also be designed to bring to light
similarities between, and unique features of, a range of
autoimmune diseases. It has been known for decades that
autoimmune disorders tend to co-aggregate in specific
individuals and nuclear families as reviewed by Baranzini
[23]. As expected, the majority of genetic research has focused
on the HLA region, which has been widely studied in the
context of autoimmune diseases for several decades. For
instance, it has been shown that HLADRB1 is associated with
susceptibility toMS, but protection from type 1 diabetes (T1D)
[10, 24]. Lately, comparison of GWAS data and gene-network
analysis suggested that gene variant signatures in non-HLA
genes are shared between MS and other autoimmune diseases,
such as rheumatoid arthritis (RA), Type 1 Diabetes and
possibly celiac disease [23]. Another study published by the
Welcome Trust Case Control Consortium (WTCCC2) tested
seven disease cohorts in parallel [25] and suggested novel MS-
specific genes (TYK2, H6PD), which were further supported
by follow-up genetic and functional studies [26, 27].
As whole, the most plausible explanation is that MS is
caused by the combined effects of genetic, epigenetic and
environmental factors, and is thus said to have a multifac-
torial etiology. It is likely that the interaction patterns
between these factors gives rise to disease subtypes, and it
is possible that eventually each subtype would be discreetly
diagnosed with high sensitivity and specificity as was the
case for NMO, reviewed above. Moreover, it is likely that
subtypes branching from and refining the categorization
into RR and SPMS/PPMS may delineate independent or
differentially dominant pathological processes typical of
each presentation, and thus susceptible and responsive to
different medications. This heterogeneity could be the result
of environmental factors (such as infectious agents, climate
or diet), genetic determinants, or interactions between them.
Understanding how such genetic polymorphisms may affect
the response to interventional therapy is the focus of
pharmacogenetic (PGx) research [28, 29].
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Multiple sclerosis therapy in practice
and in development
Currently there are no curative treatments for MS. Available
therapies provide symptom relief and can be categorized
into indications for acute, chronic and escalation therapy.
Severe acute attacks are treated by in-hospital intravenous
steroids administered for about 6 days at a time. Once
diagnosis is made and frequency of attacks exhibited by RR
patients reaches a certain threshold (determined by the
expanded disability status score (EDSS) [30] and other
physician driven input), treatment is commenced using one
of four available injectible immunosuppressants in order to
attenuate the disease (reduce the number of relapses per
year): recombinant IFN-β1a agents (avonex and rebif);
recombinant IFN-β1b (betaseron/betaferon) and glatiramer
acetate (GA, copaxone). While these immunotherapies have
been shown to be efficacious in clinical trials, they are
beneficial in only ∼30% of the RR patients [31]. Escalation
therapy includes two approved options at present: mitox-
antrone (novatrone) and natalizumab (tysabri), both of
which are associated with safety limitations.
The definition of positive response to MS intervention
therapy is in itself a debatable subject. Response can be
measured by clinical scales (most commonly the EDSS);
prescribed based on neuroimaging scans; or be a composite of
both. Still, the threshold of acceptable improvements and the
implications and relevance of short-term improvement on
long-term prognosis are largely unknown. In recent yearsMRI
has been the primary tool used for confirming diagnosis and
for establishing efficacy claims in late-stage pharmaceutical
development. However, in the case of established MS, the
correlation between clinical response and MRI measurements
has been largely weak, suggesting MRI alone is a poor
biomarker of predicted drug response [32]. Therefore, clinical
end-points remain the main diagnostic criteria in drug R&D,
with the recently published phase III trials of oral cladribine
and figolimod both employing as primary end-point the rate of
clinical relapses [33–35]. In both cases sustained progression
of disability, relapse-free rate and MRI lesion burden
improvement were used as supportive secondary end-points.
However, the definition of response may still be heteroge-
neous even when considered in the terms of “relapse rate”: the
duration of the study, the inclusion and exclusion criteria, the
definition of relapse and acute treatment protocol, population
demographics and ethnicity, are only some of the factors that
show heterogeneity across cohorts [29]. Additionally, the
optimized definition of response would incorporate elements
of patient and care-giver reported quality of life in order to
fully gage into personalized MS medicine [29].
Given the high non-response rates registered for MS
therapy and the increasing number of drugs available for
switching to as potentially beneficial alternatives, a vast
amount of effort has been invested in recent years to identify
appropriate biomarkers that indicate poor response early on.
One such recent publication suggests that developing new T2-
hyperintense lesions during IFN-β therapy predicts subse-
quent poor response with hazards ratio (HR) of 16.8 [36].
However, while useful as a research tool it is impractical and
too expensive to incorporate routine MRI scans into clinical
management of MS patients. The importance of these
findings is in the identification of distinct and measurable
pathological differences between responders and non-
responders that are evident prior to clinical manifestation. It
is therefore likely that other diagnostics, based on biological
or genetic markers, would subsequently be found which
would be useful as response predictors.
The focus of drug R&D in recent years has been devoted
to oral therapies, with five such compounds currently in
late-stage development [37]. The goal is to expand the
therapeutic choice range, provide efficacious solutions for
patients refractory to current medications, improve conve-
nience and quality of life, increase patient compliance to
treatment, enable earlier and possibly prophylactic therapy
initiation and introduce novel mechanisms of actions to
combat the disease, which may be useful for other modes of
disease rather than merely RR. Biomarkers may have a
seminal role in supporting the development of these new
medications (via differentiation strategy and target popula-
tion definition), provide helpful guidelines in regimen
tailoring in the clinic, and provide pharmacovigilance
indicators [38]. Further detail and discussion on these
aspects is provided in the safety section under the
“Pharmacogenetics in Multiple Sclerosis” heading below.
It should be noted that at the present time there are no
approved treatments for patients with the progressive mode of
disease (with the exception of mitoxantrone in worsening
progressive MS [39]), and the limited available data suggest
that RRMS available therapy is ineffective for this disease
mode [40]. It is also unclear whether early and aggressive
treatment of RR patients halts or delays the progression to
SPMS. Ultimately, our lack of understanding of the
pathophysiological processes that give rise to PPMS and
SPMS underlines our failure in developing successful treat-
ments for these phases. Research of the genetic, biological,
clinical and epidemiological characteristics of patients with
progressive disease modes as differentiated from the other
forms of the disease would eventually yield both novel drug
discovery and the development of diagnostics for treatment
allocation and monitoring of progressive MS.
Biomarkers of multiple sclerosis disease and therapy
Currently there are no biomarkers available for MS to guide
treatment selection, predict disease progression or monitor
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patients over time in the clinic. The only validated
biomarkers in use for MS diagnosis confirmation are
oligoclonal IgGs screened in CSF samples, and MRI scans.
However, both are impractical in routine practice since the
former requires an invasive procedure (i.e. lumbar puncture
for acquirement of CSF fluid samples) and is not correlated
with disease activity nor response to therapy; while the latter,
which may have benefit in progression monitoring, is
prohibitively expensive. A novel type of biomarkers has
recently been studied intensively for the purpose of response
prediction and monitoring of IFN-β therapy. Treatment by
agents from the IFN-β class induces immunogenicity
reactions in the form of binding and neutralizing antibodies
(BABs and NABs, respectively) [41]. However, not all
patients develop these antibodies and even when developed
they may disappear spontaneously over time with poor
correlation to response. Therefore the potential utility of
these markers as diagnostics in the clinic is low unless
coupled with additional markers that increase their speci-
ficity and sensitivity. Several other biomarkers are being
investigated for their utility in MS disease management and
monitoring, as reviewed in detail elsewhere [42].
One of the main stumbling blocks to the research of MS
pathoetiology and subsequent development of prognostic
biomarkers has been its neurodegenerative nature and the
fact that most studies rely on animal models with limited
applicability to the human disease. The leading animal
model used for MS research has been the experimental
autoimmune encephalomyelitis (EAE) model, which depicts
only the immunological and inflammatory axis of the
pathology. It is therefore necessary to study human subjects
with each of the disease modes in great depth and develop
biomarkers that delineate the processes that lead to clinical
outcomes. These would then serve as mechanistic markers in
the development of novel agents and will ultimately guide
treatment regimen selection and disease monitoring in the
clinic. One striking example to the limited utility of animal
models for the development of MS drugs is the discordant
efficacy and safety profiles registered for animals versus
humans in the course of drug development [43].
Pharmacogenetics in multiple sclerosis: approved
and experimental agents
Drug efficacy
Most of the PGx literature to-date has been dedicated to
IFN-β treatments and predictors of positive versus partial
or failed response (Table 1). 13 studies have been reported
between 2001 and 2009 on investigation of IFN-β
treatment efficacy, 4 of which in 2009 alone. In contrast,
2 studies were reported studying GA and only 1 studying
mitoxantrone. The majority of studies conducted prior to
2009 are small candidate gene studies investigating one to
several dozens of markers at a time. With the development
of SNP detection technologies the research scope has
expanded to investigation of whole pathways or genomes
at a time. Most importantly, while many of the early studies
lacked follow-up confirmation studies, the trend in recent
years has been to incorporate discovery and replication
cohorts into the initial publication in order to increase
validity of the findings. However, even for the more recent
publications several study design limitations exist which
result in un-interpretable and non-replicated findings with
little clinical utility information. A systematic examination
of Table 1 highlights the main flaws: First, sample sizes are
generally small although accurate phenotyping may com-
pensate, to some degree, for small patient numbers; Second,
rarely are markers studied in the context of healthy controls
and placebo treated patients in order to decipher PGx-
specific from disease progression and severity markers.
Designs that do not explore the potential influence of
prognostic markers on the PGx association are particularly
vulnerable to false-positive findings; Third, the type of
IFN-β used or the relative fraction of patients using each
one of the three class drugs has been inconsistent across
studies. This is mainly a result of the approved formularies
in different countries for non-industry sponsored trials;
Fourth, study populations vary by geographic residency and
ethnic origin both within studies and across studies and
population stratification control measurements have not
been used in most cases; Fifth, while most studies focused
on RR patients, some included a mixture of other MS
disease modes with distinct clinical course and character-
istics that may be particularly relevant to differential
treatment response patterns; Sixth, the primary response
definitions, for both positive and negative response span a
wide range of possibilities and the incorporation of both
clinical and MRI measurements is the exception rather than
the rule. Choice of extreme phenotype investigation (i.e.
“best” responders versus “worst” responders) is generally
more powerful but comes at the cost of sample size and is
critically dependent upon other factors, such as trial
duration; Seventh, as mentioned above, the scope of studied
genes and number and type of marker(s) studied within
each genomic region limits the generalizability of reported
findings. Moreover, in many instances, while overlapping
genes may have been investigated, the selected markers
within them were not identical. This is particularly relevant
when studies were conducted in different populations that
may be characterized by differential linkage disequilibrium
properties; Eighth, not all studies screened for NABs as
either an exclusion criterion or a potential confounder in
statistical analyses; Lastly, the reported studies generally do
not correct for multiple testing or multiple end-points
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studied. This is particularly concerning given the fact that
in several instances the same study population (or partially
overlapping populations) have been studied for different
PGx markers and reported in separate publications, leading
to misconception of independent findings. Overall, the
power to detect PGx effects is objectively dependent upon
factors beyond study design. Treatment response phenotypes
are a composite outcome of many different factors in
addition and complementary to genetic factors. Such
environmental effects may include diet, concomitant treat-
ments, viral infection and compliance. Moreover, low
penetrance, gene-gene and gene-environment interactions,
as well as limited statistical power are additional factors that
may have hindered progress in MS PGx research thus far.
In the context of novel drug development the need to prove
efficacy in comparison to existing medications presents new
challenges to drug developers. Drugs that show superiority to
placebo but not gold-standard comparator (such as IFN or
GA) are unlikely to be approved by regulators and have low
chances of gaining reimbursement status by health insurers.
For this purpose biomarkers have the opportunity to pinpoint
those subpopulations that may benefit from novel treatments
while having little chance of benefiting from current approved
therapy. Given the low percentage of individuals responding
favorably to existing treatments, it is likely that new
compounds with novel mechanisms of action may provide
superior efficacy to substantial proportions of the MS
population. For instance, fingolimod is a novel agent in late-
stage development that is based on a novel mode-of-action. It
is a sphingosine-1-phosphate receptor agonist that alters
lymphocyte trafficking. The drug has shown efficacy in a
2-year, placebo controlled trial (FREEDOMS), but did not
show clinical superiority to IFN-β1a in a head-to-head trial
(TRANSFORMS) in the overall study population. However,
the hypothesis that a subset of patients with a particular
genetic, genomic or biomarker profile show clear benefit
when treated with fingolimod rather than avonex has not been
reported to have been explored.
Drug safety
Adverse drug reactions (ADRs) present particular concerns
in the field of MS since most novel therapies are immuno-
suppressive in nature. Therefore, side effects tend to be
potentially life-threatening and are often not visible unless
exposure time and dosage are extended beyond the custom-
ary 12–18 months clinical trial duration. Some of these
agents deplete immune cells for sustained periods of times
which may result in life-threatening vulnerability in the face
of infection or malignancy. This safety concern has been
demonstrated through the experience with the drugs natali-
zumab (a humanized monoclonal antibody against α4β1
integrin) and mitoxantrone (a DNA-intercalating agent and
topoisomerase II inhibitor [39, 44]). In fact, natalizumab was
withdrawn from the market for 18 months in 2005, but has
gained increased popularity since its re-introduction, exceed-
ing $1B in 2009. 24 ADR cases of progressive multifocal
leukoencephalopathy (PML) were reported prior to with-
drawal and 11 more (including 4 deaths) since reintroduction.
Mitoxantrone, on the other hand, is associated with severe
immunosuppressive and cardiovascular side effects. The rare
ADRs associated with both natalizumab and mitoxantrone
have deemed their indication only to severe and non-tolerant
cases, since there are currently no validated, specific and
sensitive markers that would pinpoint individuals prone to
develop these events. In the case of mitoxantrone a recent
study suggested PGx markers in the ATP-binding cassette
transporters (ABC), which carry and eliminate the drug from
its target cells [45] (Table 1). While small and heterogeneous
with respect to nature of ADR (i.e. severe cardiovascular or
hematological adverse events were lumped together) as well
as treatment regimen (patients received either mono- or
combination therapy), the study presents a first attempt to
identify genetic markers of mitxantrone ADRs. Such a marker
could serve as a screening tool prior to therapy prescription
and counter-indicate therapy for individuals at high risk for
ADR development. In this fashion the majority of patients that
are not at risk of developing the event would benefit from the
option of starting treatment with one of these agents earlier in
the disease course due to a “personalized” favorable benefit-
risk profile. Such a study case has been proven efficacious and
safe in the treatment of HIV with abacavir, which is associated
with a hyper sensitivity ADR. The development of a genetic
marker, HLA-B*5701, has recently been adopted into clinical
guidelines as indicator of treatment allocation and has reduced
the incidence of hyper sensitivity reactions to miniscule levels
[46, 47]. Furthermore, various ADRs of common therapies
have by now been confirmed to be highly associated with
specific genetic markers that demonstrate high predictive
power [48–51].
Overall, pharmacogenetic research of the ADRs associated
with approvedMS treatments has been limited thus far. This is
mostly due to the fact that chronic treatments are relatively
safe, and the experience with escalation therapy has been
limited with little availability of genetic material for the
purpose of marker research and diagnostic development. IFN-
β therapy in general is associated with ADRs such as flu-like
symptoms (experienced by about a third of treated patients),
depression and transient laboratory abnormalities [52], while
for GA the majority of ADRs are limited to local brief reaction
at the site of injection. These ADRs are known to reduce
patients’ adherence to medication, but since they are rarely
severe there has been no research of diagnostic markers.
Novel oral treatments in development present a significant
quality-of-life improvement to patients who are now limited to
injectable options, but these new agents are also associated
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with a concerning safety profile. For instance, the recently
concluded phase III trials for fingolimod reported increased
infections, liver-function test abnormalities, cardiovascular
disorders, as well as themechanism-based expected leucopenia
and lymphopenia [33, 35]. Similarly, cladribine treatment was
associated with ADRs of infections and neoplasms [34].
Lymphocytopenia was again markedly more frequent in
cladribine treated patients (27%) as expected given its
selective induced apoptosis effects in T-lymphocytes and
CD19+ B-lymphocytes. ADRs of lymphopenia increased
with dose of both cladribine and fingolimod. Genetic or
genomic variants may exist which predispose individual to
react more strongly upon treatment and may therefore benefit
from tailored decreased dosing regimen. It remains to be seen
whether biological samples have been collected and studied
to identify such markers of ADRs.
Implications of pharmacogenetics for prediction
and personalization in multiple sclerosis
Healthcare systems worldwide are gradually adopting
models of comparative-effectiveness, where demonstrated
favorable benefit-cost profiles serve as the basis for inclusion
in national formularies (e.g. UK) or health insurance
reimbursement programs (e.g. US). It is becoming clear that
“blockbuster drugs” will be few and far between in years to
come. It is expected that demonstrated superior efficacy in
subpopulations diagnostically identified via PGx markers
will serve to qualify newly approved medicines, as well as
serve as means for economic health management in choosing
generic versus branded therapeutics [53]. PGx markers are
already becoming important factors in regulatory approval
of new medicines and are being incorporated into existing
drug labels [54–56]. MS clinical management is a case in
point. Traditional therapy with IFN-β and GA has proven
to be disappointing and selection of first or subsequent
switch therapy is done currently by trial-and-error [57]. On
the other hand, novel treatments are about to enter the
market. These innovative treatments are associated with
concerning side effects and the lack of longitudinal medical
experience of treating neurologists poises a considerable
entry to market barrier. It is therefore a pressing priority to
identify treatment response predictive diagnostics (Fig. 1).
Overall, PGx research has failed to identify any major
genetic contributors to phenotypes of MS drug efficacy
Fig. 1 Scheme of Tailored Therapeutics in Multiple Sclerosis
Management by Integrated Pharmacogenetic and Other Clinical and
Diagnostic Measures. The framework of Personalized, Predictive and
Preventative Multiple Sclerosis Management relies on integrative
analysis of input from diagnostic tests with proven utility in selection
of treatment regimen for the individual patient. In this fashion, blood
samples (or cheek swabs / spit samples) are collected from the patient
upon early signs of disease development. DNA is extracted and key,
validated genetic markers of disease progression /subtype and
response to marketed drugs (safety and efficacy indicators) are
genotyped. The genetic data is then analyzed in combination with
other validated disease and treatment response variables, including
indicators of clinical characteristics, MRI imaging, and / or other
biomarkers in body fluids. Specific algorithms provide the physician
with predictive pharmacogenetics- and bioinformatics-based tools to
allow informed medical decision prior to initiation of pharmacological
intervention. Hospitalizations, treatment switching and inadequate
efficacy results are thus considerably reduced, leading to improved
patients’ medical care management and quality of life, as well as a
decrease in healthcare costs
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and/or safety thus far. However, we propose that the lion’s
share of research conducted thus far has been based on
inconsistent study designs, small population sizes, limited
scientific scope, heterogeneous response and non-response
definitions and little functional experimentation follow-up
(Table 1). The substantial improvement in all of these
categories seen through 2009 and the expansion of research
into methxantrone, in addition to IFN- β and GA PGx,
marks a trend for change in the quality and utility of results
coming out of contemporary research. While it is possible
that genetic variants do not serve as significant and useful
predictors of any MS treatment response, the poor level of
evidence available today contributes little to support or
refute this hypothesis. To this end, the recent establishment
of a European network of research groups that promotes MS
PGx research (the United Europeans for development of
pharmacogenetics in MS network- UEPHA*MS) [58]
denotes an international effort toward standardization and
harmonization of methodology in order to maximize the
usefulness of study results and to allow directly interpretable
replication analyses. Expansion of the network to include
non-European groups will further allow the generalizability
of outcomes to other world populations [59].
It is interesting to mention in the context of MS PGx
research, that treatment response to another interferon
therapy, peginterferon-alpha-2 in combination with ribavi-
rin, used for the treatment of hepatitis C viral infection has
been recently tightly associated with a genetic marker near
the IL28B gene, encoding IFN-λ-3 [60]. This report further
supports the notion that adequately powered and well-
designed MS PGx studies may be able to identify markers
that will be useful in future clinical management of
immunomodulatory and other MS treatments. It is our
belief that with the establishment of the above international
consortia, dedicated to standardized and harmonized study
designs and sample handling procedures, MS PGx research
will unravel treatment response mechanisms and promote to
the development of predictive diagnostics integrated with
tailored therapeutics.
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